ALLMedicine™ Cardiogenic Shock Center

Oct 23rd, 2021 - The ideal timing of a durable assist device implantation in patients with end-stage heart failure presenting with INTERMACS profile I is still controversial. The data on extracorporeal life support (ECLS) bridge to durable left ventricular assist ...

Oct 23rd, 2021 - An emerging therapeutic modality, ECPELLA, which combines a transvalvular microaxial left ventricular (LV) assist device, Impella, and venoarterial membrane oxygenation (VA-ECMO), has been applied for patients with refractory cardiogenic shock. Du...

Oct 21st, 2021 - Previous reports have described non-ischaemic cardiomyopathy related to a variety of autoimmune diseases. However, very few case reports describe Sjögren disease as a contributing factor to cardiomyopathy. We report the case of a 69-year-old woman...

Oct 20th, 2021 - Cardiogenic shock (CS) is a complex multifactorial clinical syndrome, developing as a continuum, and progressing from the initial insult (underlying cause) to the subsequent occurrence of organ failure and death. There is a large phenotypic variab...

Oct 16th, 2021 - Immune checkpoint inhibitors are new immunotherapy drugs globally used for many malignancies, including renal cell carcinoma. Myocarditis as an immune-related adverse event is rare but highly fatal, suggesting that its frequency may be higher than...

Sep 8th, 2021 - Eligible patients with severe cardiogenic shock will be randomized to one of the two arms: immediate ECMO therapy or early conservative therapy. In the invasive group, veno-arterial ECMO will be implanted according to the local practice with flow ...

Sep 5th, 2021 - Mechanical complications must be carefully searched for in any patient with an acute coronary syndrome and signs of cardiogenic shock, as prompt diagnosis and immediate surgery often represent the only effective treatment for such ominous conditio...

Aug 30th, 2021 - The prospective, interventional, randomised controlled and blinded ECMOsorb study investigates in critically ill patinets with cardiogenic shock and with veno-arterial ECMO (VA-ECMO) treatment the impact of an extracorporeal cytokin hemadsorption ...

Aug 20th, 2021 - Reperfusion therapy for acute ST segment elevation myocardial infarction (STEMI) can significantly reduce mortality, but patients may still have heart failure and adverse cardiovascular events due to massive myocardial loss. About 20% of patients ...

Aug 4th, 2021 - Randomization: Patients will be randomized in the 6 hours following ECMO start in the normoxemia or in the hyperoxemia group. Randomization will be stratified on center, and medical or postcardiotomy indication for ECMO. Description of experimenta...

Oct 8th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. This week's literature features new descriptions of myocarditis linked to the two available mRNA vaccines against SARS-CoV-2. They tell a story la...

Oct 6th, 2021 - Robert C. Doebele, MD, PhD Treatment with entrectinib (Rozlytrek) led to an overall response rate (ORR) of 77% and a median duration of response (DOR) of 24.6 months in patients with ROS1 fusion—positive non–small cell lung cancer (NSCLC), accord...

Sep 21st, 2021 - A large multicenter study provides further evidence supporting the rationale for multidisciplinary teams for cardiogenic shock, one of the most lethal diseases in cardiovascular medicine. The analysis of 24 critical care ICUs (CICUs) in the Critic...

Aug 6th, 2021 - A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent over the other. Patients treated with milrinone and dob...

May 12th, 2021 - Although the ISCHEMIA trial is a touchstone in the management of patients with stable ischemic heart disease (SIHD), its population does not reflect most patients seen in US practice today, new research suggests. The 2019 landmark trial challenged...